Cargando…

Mid-term results of mitral valve palsty in patients with mitral sclerotic lesion

BACKGROUND: Mitral valve repair is preferred over prosthetic replacement. We surgically repaired mitral valve with degenerated sclerotic lesion and demonstrated mid-term results. METHODS: Mitral valve plasty (MVP) was performed with several procedures including ring annuloplasty, leaflet slicing and...

Descripción completa

Detalles Bibliográficos
Autores principales: Hirota, Masanori, Isomura, Tadashi, Katsumata, Chieko, Ito, Fusahiko, Watanabe, Masazumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862176/
https://www.ncbi.nlm.nih.gov/pubmed/27160266
http://dx.doi.org/10.1186/s13019-016-0473-4
_version_ 1782431322438893568
author Hirota, Masanori
Isomura, Tadashi
Katsumata, Chieko
Ito, Fusahiko
Watanabe, Masazumi
author_facet Hirota, Masanori
Isomura, Tadashi
Katsumata, Chieko
Ito, Fusahiko
Watanabe, Masazumi
author_sort Hirota, Masanori
collection PubMed
description BACKGROUND: Mitral valve repair is preferred over prosthetic replacement. We surgically repaired mitral valve with degenerated sclerotic lesion and demonstrated mid-term results. METHODS: Mitral valve plasty (MVP) was performed with several procedures including ring annuloplasty, leaflet slicing and decalcification. RESULTS: There were 19 males and 19 females with a mean age of 67 ± 12 y.o (n = 38). All patients were successfully treated MVP except one case with unrepairable injuries of the thin leaflet. In patients underwent MVP (n = 37), MVP included ring annuloplasty with a rigid full ring of 32 ± 2 mm (n = 37), leaflet slicing (n = 37), decalcification (n = 15) and artificial chordae (n = 14). Mitral valve area was statistically enlarged by MVP (1.65 ± 0.57 vs 2.51 ± 0.58 cm(2), p < 0.001). Left atrial diameter was statistically reduced after the operation (55 ± 10 vs 46 ± 9 mm, p < 0.001). Severity of MR and right ventricular systolic pressure (RVSP) were statistically decreased after the operation (MR; 1.8 ± 1.0 vs 0.7 ± 0.9, p < 0.001, RVSP; 38 ± 15 vs 30 ± 9 mm Hg, p < 0.001). There were 4 cases with residual MR (Grade II, n = 3; Grade III, n = 1). The 30-days mortality was 0 %. There was one late death due to non-cardiogenic cause (the 3-year survival rate of 97 %) and no redo case due to deterioration of the mitral valve during follow-up period of 21 ± 13 months. CONCLUSIONS: Successful mid-term survival and freedom from reoperation might expect to the durability of MVP in patients with mitral sclerotic lesion.
format Online
Article
Text
id pubmed-4862176
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48621762016-05-11 Mid-term results of mitral valve palsty in patients with mitral sclerotic lesion Hirota, Masanori Isomura, Tadashi Katsumata, Chieko Ito, Fusahiko Watanabe, Masazumi J Cardiothorac Surg Research Article BACKGROUND: Mitral valve repair is preferred over prosthetic replacement. We surgically repaired mitral valve with degenerated sclerotic lesion and demonstrated mid-term results. METHODS: Mitral valve plasty (MVP) was performed with several procedures including ring annuloplasty, leaflet slicing and decalcification. RESULTS: There were 19 males and 19 females with a mean age of 67 ± 12 y.o (n = 38). All patients were successfully treated MVP except one case with unrepairable injuries of the thin leaflet. In patients underwent MVP (n = 37), MVP included ring annuloplasty with a rigid full ring of 32 ± 2 mm (n = 37), leaflet slicing (n = 37), decalcification (n = 15) and artificial chordae (n = 14). Mitral valve area was statistically enlarged by MVP (1.65 ± 0.57 vs 2.51 ± 0.58 cm(2), p < 0.001). Left atrial diameter was statistically reduced after the operation (55 ± 10 vs 46 ± 9 mm, p < 0.001). Severity of MR and right ventricular systolic pressure (RVSP) were statistically decreased after the operation (MR; 1.8 ± 1.0 vs 0.7 ± 0.9, p < 0.001, RVSP; 38 ± 15 vs 30 ± 9 mm Hg, p < 0.001). There were 4 cases with residual MR (Grade II, n = 3; Grade III, n = 1). The 30-days mortality was 0 %. There was one late death due to non-cardiogenic cause (the 3-year survival rate of 97 %) and no redo case due to deterioration of the mitral valve during follow-up period of 21 ± 13 months. CONCLUSIONS: Successful mid-term survival and freedom from reoperation might expect to the durability of MVP in patients with mitral sclerotic lesion. BioMed Central 2016-05-10 /pmc/articles/PMC4862176/ /pubmed/27160266 http://dx.doi.org/10.1186/s13019-016-0473-4 Text en © Hirota et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Hirota, Masanori
Isomura, Tadashi
Katsumata, Chieko
Ito, Fusahiko
Watanabe, Masazumi
Mid-term results of mitral valve palsty in patients with mitral sclerotic lesion
title Mid-term results of mitral valve palsty in patients with mitral sclerotic lesion
title_full Mid-term results of mitral valve palsty in patients with mitral sclerotic lesion
title_fullStr Mid-term results of mitral valve palsty in patients with mitral sclerotic lesion
title_full_unstemmed Mid-term results of mitral valve palsty in patients with mitral sclerotic lesion
title_short Mid-term results of mitral valve palsty in patients with mitral sclerotic lesion
title_sort mid-term results of mitral valve palsty in patients with mitral sclerotic lesion
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4862176/
https://www.ncbi.nlm.nih.gov/pubmed/27160266
http://dx.doi.org/10.1186/s13019-016-0473-4
work_keys_str_mv AT hirotamasanori midtermresultsofmitralvalvepalstyinpatientswithmitralscleroticlesion
AT isomuratadashi midtermresultsofmitralvalvepalstyinpatientswithmitralscleroticlesion
AT katsumatachieko midtermresultsofmitralvalvepalstyinpatientswithmitralscleroticlesion
AT itofusahiko midtermresultsofmitralvalvepalstyinpatientswithmitralscleroticlesion
AT watanabemasazumi midtermresultsofmitralvalvepalstyinpatientswithmitralscleroticlesion